Summary
56 / 100 · Bulios Score
What speaks for it
- Out of every 100 AUD of revenue, 13 AUD is left as free cash.
- It could repay all its net debt from 0.1 years of operating profit.
What to watch
- It pays out more in dividends than it earns: 155% of profit.
- Earnings per share fell by 21% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 58.6 AUD for 1 AUD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (AUD)
Diluted EPS (AUD)
- Analyst estimate
Revenue grew by 9.3% a year over 5 years. Over the last 3 years it grew by 6.4% a year. For the next fiscal year analysts expect revenue to grow by 3.3%. Earnings per share fell by 21% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 AUD of revenue goes
- Cost of sales 29 AUD
- Research and development 14 AUD
- Sales and administration 44 AUD
- Taxes and other 6.6 AUD
- Net profit 6.3 AUD
Net profit, industry median (Medical - Devices) 6.9 AUD
Out of every 100 AUD of revenue, 6.3 AUD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 2.65%
- Paid out of profit
- 155%
- Raised in a row
- 4 years
You receive $2.44 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.